Edition:
United States

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

289.93USD
29 Jul 2016
Change (% chg)

$0.90 (+0.31%)
Prev Close
$289.03
Open
$288.85
Day's High
$290.46
Day's Low
$286.80
Volume
1,338,487
Avg. Vol
1,835,383
52-wk High
$338.51
52-wk Low
$223.02

Select another date:

Mon, Jul 25 2016

BRIEF-Enigma biomedical announces research collaboration agreement with Biogen Inc and Merck

* Collaboration focused on qualification and validation of Tau imaging agent developed by Merck, MK-6240

Biogen's profit easily beats Street view; CEO to leave

Biogen Inc on Thursday reported second quarter profit that blew past Wall Street estimates and significantly raised its full-year earnings forecast, while announcing that Chief Executive George Scangos would step down in the coming months once a successor is found.

UPDATE 2-Biogen's profit easily beats Street view; CEO to leave

July 21 Biogen Inc on Thursday reported second quarter profit that blew past Wall Street estimates and significantly raised its full-year earnings forecast, while announcing that Chief Executive George Scangos would step down in the coming months once a successor is found.

Biogen CEO to leave; company plans $5 bln share buyback

July 21 Biogen Inc said on Thursday Chief Executive George Scangos will leave the U.S. drugmaker in the coming months and that its board approved a $5 billion share repurchase program.

BRIEF-Biogen, Sobi to present long-term data on hemophilia drugs at conference

* Biogen and Sobi to showcase long-term efficacy and safety data from extended half-life hemophilia therapies at world federation of hemophilia 2016 world congress Source text for Eikon: Further company coverage: (Bengaluru Newsroom +1-646-223-8780)

BRIEF-Biogen SB5 accepted for review by European Medicines Agency

* Sb5, an adalimumab biosimilar referencing humira, accepted for review by european medicines agency Further company coverage: (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780)

BRIEF-Biogen and AbbVie's drug approved in EU

* Biogen and AbbVie's once-monthly zinbryta(tm) (daclizumab) approved in European Union for treatment of multiple sclerosis

BRIEF-Biogen and Abbvie's multiple sclerosis drug approved in EU

* Biogen and Abbvie's once-monthly Zinbryta (Daclizumab) approved in European Union for treatment of multiple sclerosis Source text for Eikon: Further company coverage:

Biogen's MS drug misses main goal in mid-stage study

Biogen Inc's keenly watched experimental drug for treating multiple sclerosis failed to meet the main goal of improving some symptoms in a mid-stage study, sending the company's shares down as much as 9 percent in premarket trading.

UPDATE 2-Biogen's MS drug misses main goal in mid-stage study

June 7 Biogen Inc's keenly watched experimental drug for treating multiple sclerosis failed to meet the main goal of improving some symptoms in a mid-stage study, sending the company's shares down as much as 9 percent in premarket trading.

Select another date: